Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663613 | 0.92 | CA1 (0.55) | CA1CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL3285130 | 0.88 | CA1 (0.62) | CA1CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL13197296 | 0.88 | CA1 (0.62) | CA1CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL13197284 | 0.88 | CA1 (0.62) | CA1CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL19323426 | 0.87 | CA1 (0.63) | CA1CA2ALDH1A1TSHRFABP7 | |
| SCHEMBL1663959 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL1664146 | 0.85 | TSHR (0.58) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL1451061 | 0.85 | POLB (0.51) | ALDH1A1TSHRTDP1L3MBTL1PPARG | |
| SCHEMBL5837028 | 0.84 | FABP7 (0.60) | CA1CA2ALDH1A1TDP1FABP7 | |
| SCHEMBL10119913 | 0.84 | FABP7 (0.60) | CA1CA2ALDH1A1TDP1FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011071674-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-2307476-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100113664-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2009152068-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | DDT, PCNA, AADAC | CA1 3608/4885CA2 3989/4885ALDH1A1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.